CSIMarket
 


Genocea Biosciences Inc   (GNCA)
Other Ticker:  
 

Cumulative Genocea Biosciences Inc 's Long Term Debt to Equity for Trailing Twelve Months Period

GNCA's Long Term Debt to Equity for Trailing Twelve Months Period and Long Term Debt, Equity growth


Select the Comparisons : Select the Ratio:

GNCA Long Term Debt to Equity for Trailing Twelve Months Period

(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
Y / Y Equity Growth 602.89 % 201.44 % 87.23 % -49.55 % -86.46 %
Y / Y Long Term Debt Growth -61.47 % - - - 31.54 %
Long Term Debt to Equity for Trailing Twelve Months Period 0.23 0.33 0.37 0.4 0.2
Total Ranking # 1285 # 1579 # 1442 # 1570 # 1100
Seq. Equity Growth -54.26 % -28.43 % 832.9 % 130.14 % -80.38 %
Seq. Long Term Debt Growth -28.92 % -22.17 % -17.97 % -15.1 % -


Long Term Debt to Equity for Trailing Twelve Months Period Comment for 12 Months ending at Mar 31 2022
On the trailing twelve months basis Due to long-term debt repayement of -28.92% Genocea Biosciences Inc decreased Long Term Debt to Equity for Trailing Twelve Months Period in the I. Quarter to 0.23, below company's average Long Term Debt to Equity for Trailing Twelve Months Period.
Long Term Debt to Equity for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies in Biotechnology & Pharmaceuticals industry 35 other companies have achieved lower Long Term Debt to Equity for Trailing Twelve Months Period than Genocea Biosciences Inc . While total ranking remained unchanged compare to previous quarter at no. .

What is Long Term Debt to Equity Ratio?
What is GNCA selling?
Long Term Debt to Equity GNCA in the most recent quarter
Long Term Debt to Equity for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 36
Sector # 245
S&P 500 # 1292


Long Term Debt to Equity for Trailing Twelve Months Period Statistics
High Average Low
1.66 0.61 0.12
(Jun 30 2018)   (Dec 31 2020)




Companies with similar average Long Term Debt to Equity for Trailing Twelve Months Period for 12 months ending Mar 31 2022, within Biotechnology & Pharmaceuticals Industry Long Term Debt to Equity for Trailing Twelve Months Period
Biogen Inc   0.61 
Axcella Health Inc   0.55 
Sorrento Therapeutics Inc   0.51 
Genocea Biosciences Inc   0.47 
Codiak Biosciences Inc   0.46 
Eloxx Pharmaceuticals Inc   0.42 
Oyster Point Pharma Inc   0.38 
Qiagen N v   0.37 
Pluri Inc   0.34 
Rubius Therapeutics Inc   0.34 
Kaleido Biosciences Inc   0.30 
Allena Pharmaceuticals Inc.  0.30 
Xtant Medical Holdings Inc   0.28 
Eiger Biopharmaceuticals Inc   0.26 
Neurocrine Biosciences Inc   0.26 
Candel Therapeutics Inc   0.26 
Humacyte Inc   0.24 
Poseida Therapeutics Inc   0.21 
Biomx Inc   0.20 
Fennec Pharmaceuticals Inc   0.19 
Applied Genetic Technologies Corporation  0.19 
Scholar Rock Holding Corp  0.18 
Omega Therapeutics Inc   0.17 
Inmune Bio Inc   0.16 
Bio techne Corp  0.16 
Logicbio Therapeutics Inc   0.15 
Zivo Bioscience Inc   0.15 
Taysha Gene Therapies Inc   0.13 
Surface Oncology Inc   0.13 
Orchard Therapeutics Plc  0.12 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com